The recent advisory committee review of US WorldMeds, LLC’s eflornithine (DFMO) in high-risk neuroblastoma exposed an apparent difference of opinion between US FDA reviewers and a recently issued draft guidance on the use of animal model data for confirmatory evidence.
US WorldMeds’ new drug application rests on an externally controlled trial, with confirmatory evidence primarily in the form of nonclinical...





